Bon Natural Life Ltd

Bon Natural Life Limited operates in China through its PRC subsidiaries, focusing on the manufacturing of personal care ingredients, natural health supplements, and bioactive food ingredients ¹. The company's business model revolves around providing high-quality, competitively priced products and services for the functional food, personal care, natural medicine, and other industries, serving both third-party customers and its own proprietary brands ². The company generates revenue from the sale of these products, with a mix of recurring and transactional income not explicitly detailed but implied by ongoing sales to customers ³.

The company's product categories include fragrance compounds, health supplements (powder drinks), and bioactive food ingredients ⁴. Fragrance compounds, such as sclareolide and ambroxide, are plant-extracted natural compounds used in cosmetic applications, with the company's ambroxide products boasting purity of 99.5% and above and a yield of approximately 63% ⁵. Health supplements, primarily powder drinks, include prebiotics series aimed at intestine rejuvenation and probiotic proliferation ⁶. Bioactive food ingredients encompass fruit juice concentrates and extracts like apple polyphenol, milk thistle extracts, and phloretin, used for various health benefits and as food additives and nutritional supplements ⁷.

For the fiscal year ended September 30, 2025, total revenue was $18,670,684 ⁸, a decrease of 21.7% from $23,844,556 in fiscal year 2024 ⁹. Gross profit for fiscal year 2025 was $3,878,821 ¹⁰, resulting in a gross margin of 20.8% ¹¹, down from 29.8% in the prior year ¹². Operating expenses totaled $5,502,036 ¹³, leading to an operating loss of $1,623,215 ¹⁴. Net loss for the period was $2,049,431 ¹⁵, with a net loss attributable to Bon Natural Life Limited of $1,994,768 ¹⁶. Basic and diluted EPS were both $(0.72) ¹⁷. As of September 30, 2025, current assets were $45,760,451 ¹⁸, total assets were $85,185,615 ¹⁹, current liabilities were $26,308,460 ²⁰, total liabilities were $27,187,876 ²¹, and total equity was $57,997,739 ²². Cash and restricted cash stood at $6,265,978 ²³, and total debt obligations were $12,172,653 ²⁴. Net cash provided by operating activities was $141,115 ²⁵.

Year-over-year, revenue decreased by 21.7% in fiscal year 2025 compared to 2024 ²⁶. This was driven by a 50.6% decrease in health supplement (powder drinks) revenue and a 40.3% decrease in bioactive food ingredients revenue, partially offset by a 63.5% increase in fragrance compounds revenue ²⁷. Gross margin contracted by 9.0 percentage points from 29.8% in 2024 to 20.8% in 2025 ²⁸. Selling expenses increased by 61.5% to $436,933 ²⁹, general and administrative expenses rose by 28.9% to $4,310,910 ³⁰, while research and development expenses decreased by 53.5% to $754,193 ³¹.

Significant operational developments during the period include a public offering on March 16, 2025, which raised aggregate gross proceeds of $12 million ³² through the sale of 333,333 units ³³. The company also authorized a share repurchase program on May 31, 2025, for up to $1 million of its Class A ordinary shares ³⁴. On June 26, 2025, App-Chem sold 51% equity ownership of Tianjin YHX for RMB 1 ³⁵. The company also underwent a 1-for-25 reverse stock split on April 15, 2025 ³⁶, and increased its authorized share capital to 1,000,000,000 Class A ordinary shares, 50,000,000 Class B ordinary shares, and 50,000,000 preference shares ³⁷.

Management's current operating plan indicates that existing cash and restricted cash of $6.3 million ³⁸, combined with other measures, are expected to provide sufficient liquidity to cover tax liabilities and meet future liquidity needs for at least 12 months from the date of the consolidated financial statements for the year ended September 30, 2025 ³⁹. The company anticipates renewing all existing bank loans upon maturity, citing past experience and a good credit history ⁴⁰.

A major growth area for the company is the expansion of its raw materials and ingredients business, with a commitment to achieving a compound annual growth rate of no less than 30% ⁴¹ over the next two to three years. This expansion will involve increasing plant productivity, improving technology and equipment, optimizing the supply chain, and broadening sales channels, centered on the Great Health market and focusing on the core needs of the functional food and personal care industries ⁴².

Another key growth vector is the rapid expansion of the functional health business, with an intensive focus on human micro-biome health ⁴³. Over the next two to three years, the company plans to actively develop a series of functional food and personal care products designed for precise adjustment and regulation of the human micro-biome, targeting respiratory and gastrointestinal health ⁴⁴. The company expects to leverage its own natural ingredients business to provide a significant cost advantage in these efforts ⁴⁵.

Operationally, the company expects selling expenses, including salaries and advertising, to continue increasing as it plans to intensify marketing efforts to acquire new clients and promote sales ⁴⁶. General and administrative expenses, including salaries and business consulting, are also projected to increase due to plans to hire additional personnel and incur expenses related to business expansion ⁴⁷. Professional fees for legal, audit, and advisory services are expected to rise as the company operates as a public entity ⁴⁸. Research and development expenses, including salaries and material costs, are anticipated to continue increasing as the company plans to develop new products and improve its production processes ⁴⁹.

Regarding capital allocation, the company recently completed a public offering on March 16, 2025, raising aggregate gross proceeds of $12 million ⁵⁰, with net proceeds of $10,672,912 ⁵¹ used for sales network expansion, research and development, production capacity expansion, and working capital ⁵². The company also authorized a share repurchase program on May 31, 2025, for up to $1 million of its Class A ordinary shares ⁵³. The company intends to retain any future earnings to finance the expansion of its business and does not anticipate paying cash dividends in the foreseeable future ⁵⁴.

The company faces significant risks due to its operations being entirely in China, subjecting it to complex and rapidly evolving PRC laws and regulations, which can change with little notice and be interpreted inconsistently, potentially leading to delays, increased costs, negative publicity, or even cessation of business ⁵⁵. There is a risk that the Chinese government could exert more oversight and control over overseas offerings and foreign investment in China-based issuers, potentially limiting or hindering the company's ability to offer securities and causing their value to decline or become worthless ⁵⁶. The company's products have not been clinically proven safe or effective by regulatory agencies, and adverse reactions or negative publicity could harm the business ⁵⁷. Production difficulties, quality control problems, inaccurate forecasting, and reliance on third-party suppliers for raw materials could lead to product shortages, harm sales, or create inventory write-downs ⁵⁸. The company's plans for business expansion and development are dependent on raising approximately $30 million ⁵⁹ in additional capital, which may not be available on favorable terms, potentially impairing its ability to fully implement its business plan ⁶⁰. Furthermore, the company has identified material weaknesses in its internal control over financial reporting related to a lack of accounting staff with appropriate U.S. GAAP and SEC reporting knowledge, which could result in inaccuracies in financial statements and impair compliance with reporting requirements ⁶¹.

Management's overall tone emphasizes a commitment to growth and innovation within the natural products industry, particularly focusing on human micro-biome health. The company aims to leverage its advanced bio-manufacturing technologies and proprietary natural essence extraction to achieve higher yields and purity in its products, such as ambroxide and stachyose, which it believes provides a competitive advantage ⁶². Management has outlined a clear strategy for meeting competitive challenges by focusing on technology, products, and supply chain advantages to secure a larger market share and accelerate business growth ⁶³. They also intend to actively seek collaboration and cooperation opportunities with large-scale enterprises in human micro-biome-related businesses ⁶⁴. For the foreseeable future, the company intends to use earnings for research and development, to develop new products, and to expand its production capacity, and does not expect to pay any cash dividends ⁶⁵.